Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.

Roch HouotGuillaume CartronFontanet BijouSophie de GuibertGilles Andre SallesChristophe FruchartKrimo BouabdallahMarie MaerevoetPierre FeugierSteven Le GouillHervé TillyRene-Olivier CasasnovasCécile Moluçon-ChabrotEric Van Den NestePierre ZacheeMarc AndreChristophe BonnetCorinne HaiounAchiel Van HoofKoen Van EygenLysiane MolinaEmmanuelle Nicolas-VirelizierPhilippe RuminyFranck Morschhauser

Published in: Leukemia (2018)

Keyphrases

phase ii
clinical trial
open label
diffuse large b cell lymphoma
chronic lymphocytic leukemia
phase iii
randomized controlled trial
newly diagnosed
placebo controlled
low dose
combination therapy
study protocol
replacement therapy